fda warning letter compounded semaglutide september 2025 There's lots going on this month at in the world of weight loss drugs. The agency is taking a hard look at the market. Check out these new #FDA Letters Navigating Compounded Semaglutide: What Health

The wild east of semaglutide

For a 510 man, these thresholds translate to approximately 210 lbs (BMI 30) or 188 lbs with comorbidities (BMI 27)

A thoughtful conversation with a healthcare provider helps weigh the benefits, risks, costs, and personal goals before deciding

The typical beyond-use date (BUD) for compounded semaglutide is 28 to 56 days once reconstituted or once the vial is first punctured, depending on the formulation and the pharmacys stability data

Patients with Hashimoto's require careful monitoring as weight changes may affect levothyroxine requirements, and GLP-1 medications carry risks including pancreatitis and gallbladder disease

Also Read: GLPro Investigated (2026 Report) Transdermal Bioavailability for This Specific Formula The brand's "Advanced nano-delivery matrix" claim positions GLPatch as efficiently moving botanical actives through the skin